1.. INTRODUCTION
================

Before the advent of the new anti-angiogenic agents, cytokines were considered the mainstay of treatment for locally advanced or metastatic renal cell carcinoma ([rcc]{.smallcaps}) because of a lack of improved survival with either chemotherapy [@b1-co16-s1-s40] or hormonal therapy alone. Spontaneous tumour regressions and the presence of an antitumour immune response in patients with [rcc]{.smallcaps} prompted the use of immunotherapy [@b2-co16-s1-s40].

Like hormones and neurotransmitters, cytokines are a category of signalling molecules; they are used extensively in cellular communication. They can be proteins, peptides, or glycoproteins. Historically, however, the term "cytokine" has been used to refer to the immunomodulating agents such as the interleukins ([il]{.smallcaps}s) and interferons ([inf]{.smallcaps}s), interferon alfa ([inf]{.smallcaps}α) and [il]{.smallcaps}-2 being the most evaluated cytokine agents.

2.. DISCUSSION
==============

2.1. Interferon
---------------

Interferons are naturally occurring glycoproteins that have strong antiviral activity and the ability to modulate immune response and cell proliferation. The [inf]{.smallcaps}s come in three subtypes: [inf]{.smallcaps}α, [inf]{.smallcaps}β, and [inf]{.smallcaps}γ [@b3-co16-s1-s40]. The antitumour activity of [inf]{.smallcaps} is mediated by various mechanisms---immunomodulation, antiproliferative activity, inhibition of angiogenesis, regulation of differentiation, interaction with growth factors, and modulation of gene expression, among others [@b4-co16-s1-s40]. The most extensively studied is [inf]{.smallcaps}α, which has shown efficacy in [rcc]{.smallcaps}. Studies evaluating [inf]{.smallcaps}γ have been negative.

In a Cochrane meta-analysis, treatment with [inf]{.smallcaps}α was compared with treatment with a non-[inf]{.smallcaps}α control [@b5-co16-s1-s40],[@b6-co16-s1-s40]. The pooled results of four randomized control trials ([rct]{.smallcaps}s) showed that [inf]{.smallcaps}α was associated with greater remission rates \[partial ([pr]{.smallcaps}) and complete ([cr]{.smallcaps}) responses\] as compared with controls (medroxyprogesterone acetate or vinblastine). The pooled response rates were 12.5% for [inf]{.smallcaps}α and 1.5% for controls, with a pooled odds ratio ([or]{.smallcaps}) of 7.61 \[95% confidence interval ([ci]{.smallcaps}): 3.02 to 19.2\]. Treatment with [inf]{.smallcaps}α was associated with reduced 1-year mortality ([or]{.smallcaps}: 0.56; 95% [ci]{.smallcaps}: 0.40 to 0.77). A subgroup analysis that compared studies using the recombinant subtypes [inf]{.smallcaps}α2a and [inf]{.smallcaps}α2b showed no difference between the two subtypes in either objective response or 1-year survival.

A meta-analysis by Wirth [@b7-co16-s1-s40] of 1042 patients found that the overall proportion of responses ([cr]{.smallcaps}s and [pr]{.smallcaps}s) to [inf]{.smallcaps}α was 12%. The [cr]{.smallcaps}s were rare. In patients with prior nephrectomy and in those with lung metastases, the proportion of objective responses was as high as 44%. The average time from the start of treatment to an objective response was about 3--4months. Metastases of the central nervous system tended not to respond to interferon, and soft-tissue disease tended to respond more readily than did metastases to bone.

A recent systematic review by the Cancer Care Ontario Program in Evidence-Based Care \[[cco-pebc]{.smallcaps} (Canil C, Hotte S. Interferon-alfa in the treatment of patients with inoperable locally advanced or metastatic renal cell cancer, a clinical practice guideline. In preparation)\] included eight randomized control trials [@b8-co16-s1-s40]--[@b16-co16-s1-s40] that directly evaluated the use of [inf]{.smallcaps}α in locally advanced or metastatic [rcc]{.smallcaps}. These trials compared [inf]{.smallcaps}α alone or in combination with other agents against control therapies considered to have little or no activity in [rcc]{.smallcaps}. The overall hazard ratio ([hr]{.smallcaps}) for death was 0.79, indicating a 21% reduction in the risk of death for patients treated with [inf]{.smallcaps}α. The odds of objective response for patients receiving [inf]{.smallcaps}α-containing regimens (4.4%--20%) were almost 7 times those for patients in control groups (0%--3%). Overall, toxicity appeared to be worse with [inf]{.smallcaps}α than with non-[inf]{.smallcaps}α therapy. The most common adverse events after 12 weeks of treatment with [inf]{.smallcaps}α were anorexia, fatigue, dry mouth, and rigors. No toxic deaths were reported.

Doses and modality of administration of [inf]{.smallcaps}α varied across the trials. It is unclear whether [inf]{.smallcaps}α has a dose--response effect; however, it is likely that toxicity depends on dose and schedule. In view of this understanding, it was the consensus of the authors of the review that use of the dose and schedule from the largest [rct]{.smallcaps} showing benefit is reasonable [@b8-co16-s1-s40],[@b9-co16-s1-s40]. That trial gave an initial subcutaneous dose of 5×10^6^ IU, followed by 10×10^6^ IU subcutaneously on a thrice-weekly schedule for a total of 12 weeks unless disease progresses or an objective response is obtained. Treatment may be continued after 12 weeks in responding patients.

2.2. Interferon After Cytoreductive Surgery
-------------------------------------------

The [cco]{.smallcaps}-[pebc]{.smallcaps} performed a meta-analysis of two randomized controlled trials comparing cytoreductive nephrectomy and [inf]{.smallcaps}α2b with [inf]{.smallcaps}α2b alone in patients with metastatic [rcc]{.smallcaps} [@b17-co16-s1-s40]. Overall survival ([os]{.smallcaps}) and response were assessed. The [inf]{.smallcaps}α2b was initiated within 1 month of nephrectomy, was escalated to a subcutaneous dose of 5×10^6^ IU/m^2^ thrice weekly, and was continued until disease progression or completion of 52 weeks of therapy. In both trials, responses to [inf]{.smallcaps}α2b were not significantly different between the trial arms. The pooled response rates were 6.9% for nephrectomy with [inf]{.smallcaps}α2b and 5.7% for [inf]{.smallcaps}α2b alone (*p* = 0.60). The pooled median survival time for patients treated with nephrectomy and [inf]{.smallcaps}α2b was 13.6 months as compared with 7.8 months for patients treated with [inf]{.smallcaps}α2b alone (*p* = 0.002). Nephrectomy was associated with a 31% lower risk of death (pooled [hr]{.smallcaps}: 0.69; 95% [ci]{.smallcaps}: 0.55 to 0.87). A survival advantage was maintained across all 3 stratification variables, which included performance status, site of metastases, and disease measurability. However, the magnitude of benefit seemed to greater for patients with a performance status of 0 as compared with 1 (28% vs. 22%), non-measurable as compared with measurable disease (51% vs. 25%), and lung-only as compared with not lung-only metastatic disease (37% vs. 30%). Combined therapy with nephrectomy and [inf]{.smallcaps}α2b was well tolerated by most patients. Overall, the data support the recommendation that nephrectomy be considered in all patients fit enough to undergo the procedure.

2.3. Interleukin-2
------------------

The antitumour activity of the [il]{.smallcaps}-2 T-cell growth factor protein is not completely understood, but is believed to occur at least in part by direct activation of lymphoid cells. The [il]{.smallcaps}-2 affects proliferation and maturation of effector cells, enhancing the function of natural killer T cells, generating lymphokine-activated killer cells, and stimulating T-cell and B-cell growth, resulting in a reduction in tumour growth. The [il]{.smallcaps}-2 has no direct antitumour activity [@b18-co16-s1-s40]. Administration of [il]{.smallcaps}-2 can use any of three routes: high-dose [il]{.smallcaps}-2 bolus, continuous intravenous infusion, or subcutaneous injection.

A recent systematic review conducted by Hotte *et al.* [@b19-co16-s1-s40] included [rct]{.smallcaps}s or meta-analyses of [rct]{.smallcaps}s comparing treatments with [il]{.smallcaps}-2 against regimens without [il]{.smallcaps}-2 in patients with unresectable or metastatic [rcc]{.smallcaps} and reporting data on at least one of the following outcomes: survival \[[os]{.smallcaps} or progression-free survival ([pfs]{.smallcaps}), or time to progression\], response rates, toxicity, or quality of life. The review excluded [rct]{.smallcaps}s that compared [il]{.smallcaps}-2 with surgery or radiotherapy. Six [rct]{.smallcaps}s were included in the review. Across these trials, 1098 eligible patients were randomized. None of the trials was placebo-controlled. All of the trials assessed [il]{.smallcaps}-2 in combination with other agents, and two of the three-arm trials also included a single-agent [il]{.smallcaps}-2 arm. Four trials evaluated subcutaneous [il]{.smallcaps}-2, and two trials evaluated intravenous administration at a dose of 18×10^6^ IU/m^2^.

In the five trials that reported objective response rates, the overall weighted objective response rates for [il]{.smallcaps}-2--based regimens as compared with regimens that were not based on [il]{.smallcaps}-2 were 13.3% (range: 9%--39%) and 5.3% (range: 0%--20%; *p* ≤ 0.001) respectively. Pooled analysis of 1-year mortality data showed no statistically significant difference between [il]{.smallcaps}-2--based regimens and non--[il]{.smallcaps}-2 controls (risk ratio: 0.94; 95% [ci]{.smallcaps}: 0.67 to 1.30; *p* = 0.69).

A Cochrane systematic review [@b5-co16-s1-s40],[@b6-co16-s1-s40] also reviewed [il]{.smallcaps}-2 with a range of other immunotherapies. Results from that meta-analysis also showed no differences between [il]{.smallcaps}-2 regimens and non--[il]{.smallcaps}-2 regimens in both 1-year mortality and remission rates.

Overall, [il]{.smallcaps}-2--containing regimens appeared more toxic than did non--[il]{.smallcaps}-2 regimens, but the side effects were described as moderately- to well-tolerated by most patients in most of the trials. The most common grades 3 and 4 toxicities associated with [il]{.smallcaps}-2--based treatment were fever, chills, malaise, anorexia, oliguria, nausea or vomiting (or both), diarrhea, skin rash or allergies, hypotension, pulmonary distress, and central nervous system and cardiac toxicity.

2.4. High-Dose Interleukin-2
----------------------------

High-dose [il]{.smallcaps}-2 has been defined as [il]{.smallcaps}-2 administered as an intravenous bolus of at least 600,000IU/kg every 8 hours, or a dose exceeding 65×10^6^ IU/m^2^ daily.

The review by Hotte *et al.* and the Cochrane review [@b5-co16-s1-s40],[@b6-co16-s1-s40],[@b19-co16-s1-s40] did not identify any randomized phase [iii]{.smallcaps} trials comparing high-dose intravenous [il]{.smallcaps}-2 with a non--[il]{.smallcaps}-2 control or placebo; thus the true clinical effectiveness of the treatment remains unclear. For this reason, it is impossible to recommend use of high-dose intravenous [il]{.smallcaps}-2 outside of clinical trials or investigative settings.

A published series by Fisher and colleagues combining data from seven nonrandomized single-arm phase [ii]{.smallcaps} trials suggests that approximately 9% of patients can experience complete and long-lasting remissions with high-dose [il]{.smallcaps}-2. The lack of control subjects makes interpretation of these data difficult. Proper patient selection is important given the toxicity associated with high-dose [il]{.smallcaps}-2 therapy, and some attempts have been made with some success to identify tissue markers that predict for better response. Atkins *et al.* [@b20-co16-s1-s40] found that expression levels of carbonic anhydrase [ix]{.smallcaps} ([caix]{.smallcaps}) in tumour correlate with response. Survival was also significantly longer in patients whose tumour specimens stained highly for [caix]{.smallcaps} relative to patients whose tumour specimens expressed low levels of [caix]{.smallcaps}. Survival for more than 5 years was seen only in patients whose tumour specimens highly expressed [caix]{.smallcaps}.

2.5. Combination Regimens of Interferon and Interleukin-2
---------------------------------------------------------

The Cochrane systematic review [@b5-co16-s1-s40],[@b6-co16-s1-s40] included two trials comparing [il]{.smallcaps}-2 plus [inf]{.smallcaps}α with [inf]{.smallcaps}α alone. In both of those trials, [il]{.smallcaps}-2 combined with [inf]{.smallcaps}α was associated with a statistically significant improvement in response rates as compared with [inf]{.smallcaps}α alone, but that response did not translate into an improvement in survival at 1year.

In a trial by Atzpodien and colleagues [@b21-co16-s1-s40], median survival was longer for patients treated with a combination of [il]{.smallcaps}-2 and [inf]{.smallcaps}α than with either 5-fluorouacil \[5-[fu]{.smallcaps} (25 months; *p* = 0.04)\] or 13*-cis-*retinoic acid (27 months; *p* = 0.02) than for patients treated with a combination of [inf]{.smallcaps}α2a and vinblastine (16 months). In an earlier trial by the same group [@b22-co16-s1-s40], a statistically significantly longer median survival was observed with [il]{.smallcaps}-2 combined with [inf]{.smallcaps}α and 5-[fu]{.smallcaps} than with tamoxifen (24 months vs. 13 months; *p* = 0.03). Furthermore, median [pfs]{.smallcaps} at 1 year was significantly longer for patients treated with [il]{.smallcaps}-2 combined with [inf]{.smallcaps}α2a (20 months) than for patients treated with single-agent [il]{.smallcaps}-2 (15 months; *p* = 0.01) or single-agent [inf]{.smallcaps}α2a (12 months; *p* = 0.01).

2.6. Interferon Compared with Interleukin-2
-------------------------------------------

The Cochrane systematic review [@b5-co16-s1-s40],[@b6-co16-s1-s40] also analyzed trials comparing [il]{.smallcaps}-2--based regimens with [inf]{.smallcaps}α alone. The [il]{.smallcaps}-2--based immunotherapies were not observed to be superior to [inf]{.smallcaps}α, but [il]{.smallcaps}-2--containing regimens were associated with greater toxicity.

2.7. Interferon Combined with Inhibitors of Angiogenesis
--------------------------------------------------------

Many of the new anti-angiogenic agents being studied in patients with [rcc]{.smallcaps} have been compared with [inf]{.smallcaps}s, either [inf]{.smallcaps} as a single agent or the anti-angiogenic in combination with [inf]{.smallcaps}. Given that studies evaluating anti-angiogenic agents alone in comparison with [inf]{.smallcaps} alone are being reviewed elsewhere in this issue of *Current Oncology,* we concentrate here on studies combining [inf]{.smallcaps} and an anti-angiogenic agent.

### 2.7.1. Bevacizumab

In two large [rct]{.smallcaps}s [@b23-co16-s1-s40],[@b24-co16-s1-s40], the combination of bevacizumab and [inf]{.smallcaps} was associated with significantly longer [pfs]{.smallcaps} than was [inf]{.smallcaps}α alone. Pooling the [pfs]{.smallcaps} data from the two trials in a meta-analysis produced a [hr]{.smallcaps} of 0.68 (95% [ci]{.smallcaps}: 0.60 to 0.76; *p* \< 0.00001), which represents a 32% reduction in the risk of progression or death with combination therapy. Combination therapy was associated with more grades 3 and 4 adverse events and treatment discontinuations, but in both treatment arms, the most frequently reported grade 3 or 4 effects were [inf]{.smallcaps}α-associated toxicity. Deaths resulting from adverse effects were reported with combination (*n* = 8) and with control (*n* = 7) therapy, and three of those deaths were possibly attributable to treatment with bevacizumab. Notably, no [rct]{.smallcaps} of bevacizumab as a single agent has yet to be reported, and bevacizumab should therefore be used in combination only with [inf]{.smallcaps} at the present time.

### 2.7.2. Temsirolimus

One large trial [@b25-co16-s1-s40] of temsirolimus that included only poor-risk [rcc]{.smallcaps} patients compared temsirolimus alone with temsirolimus plus [inf]{.smallcaps}α and with [inf]{.smallcaps}α alone. The authors reported longer [os]{.smallcaps} with single-agent temsirolimus than with single-agent [inf]{.smallcaps}α (median: 10.9 months vs. 7.3 months; [hr]{.smallcaps}: 0.73; 95% [ci]{.smallcaps}: 0.58 to 0.92; *p* = 0.008). No survival benefit was observed in patients treated with the combination of temsirolimus and [inf]{.smallcaps}α, but toxicity was increased. Median [pfs]{.smallcaps} was also longer in patients treated with temsirolimus, either alone or in combination with [inf]{.smallcaps}α. Temsirolimus-based regimens were associated with significantly more grades 3 and 4 anemia, neutropenia, and thrombocytopenia; however, in general, temsirolimus alone was better tolerated than was any treatment arm that contained [inf]{.smallcaps}α.

### 2.7.3. Thalidomide

One trial [@b26-co16-s1-s40] (*n* = 342) compared the combination of thalidomide and [inf]{.smallcaps}α with [inf]{.smallcaps}α alone. No difference in [os]{.smallcaps} was observed and a 1-month improvement in [pfs]{.smallcaps} was seen with combination treatment (3.8 months vs. 2.8 months; *p* = 0.04). Based on these modest improvements and the considerable toxicity of thalidomide, this treatment should not be routinely used in patients with [rcc]{.smallcaps}.

3.. CONCLUSIONS
===============

For patients with inoperable locally advanced or metastatic [rcc]{.smallcaps}, results from recent [rct]{.smallcaps}s indicate that anti-angiogenic agents are superior to [inf]{.smallcaps}α alone and are therefore recommended as the preferred treatment option as single agents or in combination with [inf]{.smallcaps}. In circumstances in which targeted therapies cannot be used, single-agent [inf]{.smallcaps}α may still occasionally be used as a treatment option, given that it has been shown to improve survival and disease control. The benefits of combined immunotherapy (with or without chemotherapy) over [inf]{.smallcaps}α alone are unclear, and such combinations should therefore be used only in the context of clinical trials. Common side effects of [inf]{.smallcaps}α include anorexia, fatigue, nausea and vomiting, dry mouth, shivering, and mood changes. The data are still insufficient to support the routine use of high-dose intravenous [il]{.smallcaps}-2 therapy outside of a clinical trial, and the toxicity of this treatment warrants its administration in specialized centers.

Although cytoreductive therapy has been evaluated in combination with [inf]{.smallcaps} therapy and has been associated with improved survival, its role in combination with anti-angiogenic agents remains to be established.
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